Please Wait.....
Report
Genotyping Assay Market by Product & Services (Kits, Instruments,Bioinformatics), Technology (PCR, Sequencing, Microarray), Application (Pharmacogenomics, Animal Genetics), End User (PharmaBiotech Companies, Diagnostic Labs) - Global Forecast to 2029
Market Report I 2024-06-19 I 371 Pages I MarketsandMarkets
At a CAGR of 13.8% over the course of the projection period, the genotyping assay market is expected to grow from USD 19.4 billion in 2024 to USD 37.1 billion in 2029. Advances in technology and falling DNA sequencing costs are anticipated to propel this market's growth. Recently, the industry has grown at a slower rate due to the increased prevalence of hereditary illnesses. Additionally, the field of customized medicine and medication development has made genotyping a major component.
Opportunities in the market are anticipated to arise from the need for genome analysis in plants and animal livestock, an increasing emphasis on national sequencing programs aimed at establishing genetic connections with disease, and the expanding fields of applications for genotyping. On the other hand, market expansion may be somewhat hampered by the high cost of equipment.
"Reagents & Kits segment accounted for the highest CAGR"
By product & service, the market is primarily segmented into reagents and kits, instruments, GENOTYPING ASSAY services, and bioinformatics. The reagents & kits segment accounted for the largest share of the Genotyping assay in 2023. The availability of a broad variety of reagents, the rising demand for reagents due to the rising volume of GENOTYPING ASSAY tests conducted worldwide, and the comparatively lower initial outlay needed to implement reagents and kits for GENOTYPING Assay in pharmacies and diagnostic facilities are all responsible for this segment's size.
"The polymerase chain reaction (PCR) segment accounted for the market share in the genotyping assay market, by technology, during the forecast period"
By technology, the market is primarily segmented into polymerase chain reaction (PCR), microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF), and other technologies (in situ hybridization and allele-specific oligonucleotides). The PCR segment accounted for the largest share of the GENOTYPING ASSAY technology market in 2023. The main factors propelling the growth of the PCR market are the introduction of new technologies like reverse transcriptase PCR, nested PCR, hot-start PCR, allele-specific PCR, and multiplex PCR; technological developments in PCR instruments and reagents; and the growing use of PCR technologies in the domains of genetics, prenatal testing, forensics, and personalized medicine.
"Pharmacogenomics segment accounted for the highest share"
By application, the market is primarily segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment accounted for the largest share of the GENOTYPING ASSAY applications market in 2023. The primary drivers of growth in this market are the growing need for pharmacogenomics to investigate adverse drug reactions (ADRs) in clinical trials and the requirement to lower the total cost of medication development for pharmaceutical companies. The growing need for customized medication, the rise in hereditary and life-threatening illnesses, and ongoing research into effective and alternative drug delivery strategies are all anticipated to fuel the growth of the pharmacogenomics genotyping test.
"Biopharmaceutical & pharmaceutical companies segment accounted for the highest share"
By end user, the market is primarily segmented into biopharmaceutical & pharmaceutical companies, diagnostic laboratories, academic & research institutes, and other end users. The biopharmaceutical & pharmaceutical companies segment accounted for the largest share of the GENOTYPING ASSAY end-user market in 2023. The growing need for pharmacogenomics in the medication development process, the introduction of new products, and FDA recommendations to incorporate pharmacogenomics studies and GENOTYPING ASSAY in the drug discovery process are all responsible for this segment's size. Furthermore, the expansion of this market sector within GENOTYPING ASSAY is further facilitated by a rise in partnerships and funding for pharmacogenomics research.
"Asia Pacific: The fastest-growing region in cancer biomarkers market"
The global cancer biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. The Asia Pacific region is projected to register the highest CAGR during the forecast period, primarily due to the increasing financial support from public as well as private agencies, increasing number of NGS-based research projects, increasing awareness about precision medicine, and high incidence of chronic diseases.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
- By Designation: C-level (27%), Director-level (18%), and Others (55%)
- By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)
Lists of Companies Profiled in the Report:
- Thermo Fisher Scientific Inc. (US),
- Illumina, Inc. (US),
- Danaher Corporation (US),
- QIAGEN (Netherlands),
- Eurofins Scientific (Luxembourg),
- F. Hoffmann-La Roche Ltd. (Switzerland),
- Bio-Rad Laboratories, Inc. (US),
- Merck KGAA (Germany),
- Agilent Technologies (US),
- Revvity Inc. (US),
- Standard Bio Tools (US),
- PacBio (US),
- GENEWIZ Inc. (US),
- Luminex Corporation (Diasorin Company) (US),
- Oxford Nanopore Technologies Plc (UK),
- GenScript (US),
- Takara Bio Inc. (Japan),
- New England Biolabs (US),
- Promega Corporation (US),
- Tecan Trading AG (Switzerland),
- Genotypic Technology Pvt. Ltd. (India),
- BGI GROUP (China),
- Novogene Co., Ltd. (China),
- Paragon Genomics, Inc. (US),
- NeoGenomics Laboratories (US).
Research Coverage
This research report categorizes the genotyping assay market by product & services, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the optometry equipment market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the genotyping assay market. Competitive analysis of upcoming startups in the optometry equipment market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall genotyping assay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Technological advancements and reduced prices of DNA sequencing, Growing importance and use of genotyping in drug discovery and development), restraints (High manufacturing, installation, and maintenance costs of genotyping instruments), opportunities (Increasing application areas in genomics and genotyping analysis for animal genetics and agricultural biotechnology), and challenges (lack of adequate data management in genomics research) influencing the growth of the genotyping assay market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the genotyping assay market
- Market Development: Comprehensive information about lucrative markets - the report analyses the genotyping assay market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the genotyping assay market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher Corporation (US), Eurofins Scientific (Luxembourg), and QIAGEN (Netherlands). among others in genotyping assay market.
1 INTRODUCTION 51
1.1 STUDY OBJECTIVES 51
1.2 MARKET DEFINITION 51
1.2.1 INCLUSIONS & EXCLUSIONS 52
TABLE 1 GENOTYPING ASSAY MARKET: INCLUSIONS & EXCLUSIONS 52
1.3 STUDY SCOPE 53
1.3.1 SEGMENTS COVERED 53
FIGURE 1 GENOTYPING ASSAY MARKET: SEGMENTS COVERED 53
1.3.2 REGIONS COVERED 54
FIGURE 2 GENOTYPING ASSAY MARKET: REGIONS COVERED 54
1.3.3 YEARS CONSIDERED 54
FIGURE 3 GENOTYPING ASSAY MARKET: YEARS CONSIDERED 54
1.3.4 CURRENCY CONSIDERED 54
1.4 STAKEHOLDERS 55
1.5 SUMMARY OF CHANGES 55
1.5.1 RECESSION IMPACT 56
2 RESEARCH METHODOLOGY 57
2.1 RESEARCH DATA 57
FIGURE 4 GENOTYPING ASSAY MARKET: RESEARCH DESIGN 57
2.1.1 SECONDARY DATA 58
2.1.1.1 Key secondary sources 58
2.1.1.2 Key data from secondary sources 59
FIGURE 5 KEY DATA FROM SECONDARY SOURCES 59
2.1.1.3 Objectives of secondary research 59
2.1.2 PRIMARY DATA 60
2.1.2.1 Key primary sources: Demand and supply sides 60
FIGURE 6 KEY PRIMARY SOURCES: DEMAND AND SUPPLY SIDES 60
2.1.2.2 Objectives of primary research 60
2.1.2.3 Key data from primary sources 61
TABLE 2 GENOTYPING ASSAY MARKET: KEY DATA FROM PRIMARY SOURCES 61
2.1.2.4 Insights from primary experts 62
FIGURE 7 GENOTYPING ASSAY MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS 62
2.1.2.5 Breakdown of primaries 62
FIGURE 8 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 62
FIGURE 9 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION 63
2.2 MARKET SIZE ESTIMATION 63
2.2.1 BOTTOM-UP APPROACH 63
2.2.1.1 Company revenue estimation approach 64
FIGURE 10 COMPANY REVENUE ESTIMATION APPROACH 64
2.2.1.2 Company presentations and primary interviews 64
2.2.1.3 Growth forecasts 64
2.2.1.4 CAGR projections 65
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 65
2.2.2 TOP-DOWN APPROACH 65
FIGURE 12 GENOTYPING ASSAY MARKET: TOP-DOWN APPROACH 66
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 66
FIGURE 13 GENOTYPING ASSAY MARKET: DATA TRIANGULATION METHODOLOGY 67
2.4 MARKET SHARE ANALYSIS 67
2.5 STUDY ASSUMPTIONS 68
2.6 GROWTH RATE ASSUMPTIONS 68
2.7 RISK ASSESSMENT 68
TABLE 3 GENOTYPING ASSAY MARKET: RISK ASSESSMENT 68
2.8 RESEARCH LIMITATIONS 69
2.9 IMPACT OF ECONOMIC RECESSION ON GENOTYPING ASSAY MARKET 69
3 EXECUTIVE SUMMARY 71
FIGURE 14 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION) 71
FIGURE 15 GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 72
FIGURE 16 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 72
FIGURE 17 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 73
FIGURE 18 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2024 VS. 2029 (USD MILLION) 74
FIGURE 19 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2024 VS. 2029 (USD MILLION) 74
FIGURE 20 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2024 VS. 2029 (USD MILLION) 75
FIGURE 21 GENOTYPING ASSAY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 76
FIGURE 22 GENOTYPING ASSAY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 76
FIGURE 23 GENOTYPING ASSAY MARKET, BY REGION, 2024 VS. 2029 (USD MILLION) 77
4 PREMIUM INSIGHTS 78
4.1 GENOTYPING ASSAY MARKET OVERVIEW 78
FIGURE 24 TECHNOLOGICAL ADVANCEMENTS AND REDUCED PRICES OF DNA SEQUENCING TO DRIVE MARKET 78
4.2 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 79
FIGURE 25 REAGENTS & KITS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD 79
4.3 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2024 VS. 2029 79
FIGURE 26 POLYMERASE CHAIN REACTION TO POSSESS LARGEST MARKET SHARE BETWEEN 2024 AND 2029 79
4.4 GENOTYPING ASSAY MARKET, BY APPLICATION, 2024 VS. 2029 80
FIGURE 27 PHARMACOGENOMICS TO ACCOUNT FOR LARGEST MARKET SHARE DURING STUDY PERIOD 80
4.5 GENOTYPING ASSAY MARKET, BY END USER, 2024 VS. 2029 80
FIGURE 28 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO COMMAND LARGEST MARKET SHARE FROM 2024 TO 2029 80
4.6 GENOTYPING ASSAY MARKET: REGIONAL GROWTH OPPORTUNITIES (2024-2029) 81
FIGURE 29 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 81
5 MARKET OVERVIEW 82
5.1 INTRODUCTION 82
5.2 MARKET DYNAMICS 82
FIGURE 30 GENOTYPING ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 82
5.2.1 DRIVERS 83
5.2.1.1 Technological advancements and reduced prices of DNA sequencing 83
FIGURE 31 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2002-2022 83
5.2.1.2 Increasing incidence of genetic diseases and rising use of personalized medicines 84
5.2.1.3 Growing importance and use of genotyping in drug discovery and development 84
5.2.1.4 Increasing demand for bioinformatics solutions in data analysis 85
5.2.2 RESTRAINTS 85
5.2.2.1 High manufacturing, installation, and maintenance costs of genotyping instruments 85
5.2.3 OPPORTUNITIES 86
5.2.3.1 Increasing use of genomics in animal genetics and agricultural biotechnology 86
5.2.4 CHALLENGES 87
5.2.4.1 Lack of adequate data management in genomics research 87
5.2.4.2 Dearth of trained healthcare personnel for genomic sequencing data analysis 88
5.3 PRICING ANALYSIS 88
5.3.1 PRICING ANALYSIS FOR GENOTYPING ASSAY PRODUCTS, 2021-2023 88
TABLE 4 PRICING ANALYSIS TREND FOR GENOTYPING ASSAY PRODUCTS, 2021-2023 88
5.3.2 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY REGION, 2021-2023 89
TABLE 5 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY REGION, 2021-2023 89
5.4 PATENT ANALYSIS 90
FIGURE 32 PATENT APPLICATIONS FOR GENOTYPING ASSAY (NEXT-GENERATION SEQUENCING) MARKET, JANUARY 2012-MARCH 2023 90
TABLE 6 INDICATIVE LIST OF PATENTS IN GENOTYPING ASSAY (NEXT-GENERATION SEQUENCING) MARKET 91
5.5 VALUE CHAIN ANALYSIS 91
FIGURE 33 GENOTYPING ASSAY MARKET: VALUE CHAIN ANALYSIS 92
5.6 SUPPLY CHAIN ANALYSIS 92
5.6.1 PROMINENT COMPANIES 92
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 92
5.6.3 END USERS 93
FIGURE 34 GENOTYPING ASSAY MARKET: SUPPLY CHAIN ANALYSIS 93
5.7 ECOSYSTEM ANALYSIS 93
FIGURE 35 GENOTYPING ASSAY MARKET: ECOSYSTEM MAP 94
5.7.1 ROLE IN ECOSYSTEM 94
TABLE 7 GENOTYPING ASSAY MARKET: ROLE IN ECOSYSTEM 94
5.8 PORTER'S FIVE FORCES ANALYSIS 95
FIGURE 36 GENOTYPING ASSAY MARKET: PORTER'S FIVE FORCES ANALYSIS 95
TABLE 8 GENOTYPING ASSAY MARKET: PORTER'S FIVE FORCES ANALYSIS 95
5.8.1 THREAT OF NEW ENTRANTS 96
5.8.2 THREAT OF SUBSTITUTES 96
5.8.3 BARGAINING POWER OF SUPPLIERS 96
5.8.4 BARGAINING POWER OF BUYERS 96
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 96
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 97
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 97
FIGURE 37 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 97
TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 97
5.9.2 KEY BUYING CRITERIA 98
FIGURE 38 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS 98
TABLE 10 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS 98
5.10 REGULATORY ANALYSIS 99
5.10.1 REGULATORY LANDSCAPE 99
5.10.1.1 North America 99
5.10.1.1.1 US 99
TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION 100
TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 100
5.10.1.1.2 Canada 100
5.10.1.2 Europe 100
5.10.1.3 Asia Pacific 101
5.10.1.3.1 China 101
TABLE 13 CHINA: CLASSIFICATION OF MEDICAL DEVICES 101
5.10.1.3.2 Japan 102
5.10.1.3.3 India 102
5.10.1.4 Latin America 102
5.10.1.5 Middle East 102
5.11 TRADE ANALYSIS 103
5.11.1 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822) 103
TABLE 14 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017-2021 (USD) 103
5.11.2 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822) 103
TABLE 15 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017-2021 (USD) 103
5.12 TECHNOLOGY ANALYSIS 104
5.12.1 KEY TECHNOLOGIES 104
5.12.1.1 Polymerase chain reaction 104
5.12.1.2 Next-generation sequencing 104
5.12.2 COMPLEMENTARY TECHNOLOGIES 104
5.12.2.1 CRISPR-based perturbational 104
5.12.3 ADJACENT TECHNOLOGIES 104
5.12.3.1 Single-cell RNA sequencing 104
5.13 KEY CONFERENCES AND EVENTS, 2024-2025 105
TABLE 16 GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024-DECEMBER 2025 105
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 106
FIGURE 39 REVENUE SHIFT IN GENOTYPING ASSAY MARKET 106
5.15 CASE STUDY ANALYSIS 106
5.15.1 DIGITAL PCR FOR GENOTYPE QUANTIFICATION IN PASTA PRODUCTION CHAIN 106
5.16 INVESTMENT & FUNDING SCENARIO 107
6 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE 108
6.1 INTRODUCTION 109
TABLE 17 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 109
6.2 REAGENTS & KITS 109
6.2.1 INCREASING VOLUME OF GENOTYPING TESTS TO DRIVE MARKET 109
TABLE 18 GENOTYPING ASSAY REAGENTS & KITS MARKET, BY REGION, 2022-2029 (USD MILLION) 110
TABLE 19 NORTH AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 110
TABLE 20 EUROPE: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 111
TABLE 21 ASIA PACIFIC: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 111
TABLE 22 LATIN AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 112
6.3 GENOTYPING SERVICES 112
6.3.1 RISING DEMAND FOR SEQUENCING FROM HOSPITALS AND PHARMACEUTICAL COMPANIES TO PROPEL MARKET GROWTH 112
TABLE 23 GENOTYPING ASSAY SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) 113
TABLE 24 NORTH AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 113
TABLE 25 EUROPE: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 114
TABLE 26 ASIA PACIFIC: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 114
TABLE 27 LATIN AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 115
6.4 INSTRUMENTS 115
TABLE 28 GENOTYPING ASSAY INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION) 115
TABLE 29 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 116
TABLE 30 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 116
TABLE 31 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 116
TABLE 32 LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 117
TABLE 33 GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 117
6.4.1 SEQUENCERS & AMPLIFIERS 117
6.4.1.1 Decreasing cost of DNA sequencing procedures to aid market growth 117
TABLE 34 GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY REGION, 2022-2029 (USD MILLION) 118
TABLE 35 NORTH AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 118
TABLE 36 EUROPE: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 119
TABLE 37 ASIA PACIFIC: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 119
TABLE 38 LATIN AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 120
6.4.2 ANALYZERS 120
6.4.2.1 Technological advancements in high-throughput analyzers to support market growth 120
TABLE 39 GENOTYPING ASSAY ANALYZERS MARKET, BY REGION, 2022-2029 (USD MILLION) 121
TABLE 40 NORTH AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 121
TABLE 41 EUROPE: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 42 ASIA PACIFIC: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 43 LATIN AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 123
6.5 BIOINFORMATICS 123
TABLE 44 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY REGION, 2022-2029, (USD MILLION) 123
TABLE 45 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 124
TABLE 46 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 124
TABLE 47 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 125
TABLE 48 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 125
TABLE 49 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 125
6.5.1 SOFTWARE 126
6.5.1.1 High volume of sequencing and microarray tests to augment segment growth 126
TABLE 50 GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION) 126
TABLE 51 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 127
TABLE 52 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 127
TABLE 53 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 127
TABLE 54 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 128
6.5.2 SERVICES 128
6.5.2.1 Increasing public-private funding to support segment growth 128
TABLE 55 GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) 129
TABLE 56 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 57 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 130
TABLE 58 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 130
TABLE 59 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 131
7 GENOTYPING ASSAY MARKET, BY TECHNOLOGY 132
7.1 INTRODUCTION 133
TABLE 60 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 133
7.2 POLYMERASE CHAIN REACTION 133
TABLE 61 COMPARATIVE STUDY: REAL-TIME POLYMERASE CHAIN REACTION VS. DIGITAL POLYMERASE CHAIN REACTION 134
TABLE 62 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 135
TABLE 63 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022-2029 (USD MILLION) 135
TABLE 64 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION) 135
TABLE 65 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION) 136
TABLE 66 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION) 136
TABLE 67 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION) 137
7.2.1 REAL-TIME POLYMERASE CHAIN REACTION 137
7.2.1.1 Continuous automation of laboratory techniques to propel market growth 137
TABLE 68 KEY REAL-TIME POLYMERASE CHAIN REACTION PRODUCTS 137
TABLE 69 REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022-2029 (USD MILLION) 139
TABLE 70 NORTH AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 139
TABLE 71 EUROPE: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 140
TABLE 72 ASIA PACIFIC: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 140
TABLE 73 LATIN AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 141
7.2.2 DIGITAL POLYMERASE CHAIN REACTION 141
7.2.2.1 High cost of instruments and lack of knowledge among end users to limit market growth 141
TABLE 74 KEY DIGITAL POLYMERASE CHAIN REACTION PRODUCTS 141
TABLE 75 DIGITAL POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022-2029 (USD MILLION) 142
TABLE 76 NORTH AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142
TABLE 77 EUROPE: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 143
TABLE 78 ASIA PACIFIC: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 143
TABLE 79 LATIN AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 144
7.3 MICROARRAYS 144
7.3.1 HIGH DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET 144
TABLE 80 KEY MICROARRAYS 145
TABLE 81 GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY REGION, 2022-2029 (USD MILLION) 146
TABLE 82 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION) 146
TABLE 83 EUROPE: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION) 147
TABLE 84 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION) 147
TABLE 85 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION) 148
7.4 SEQUENCING 148
TABLE 86 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 148
TABLE 87 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY REGION, 2022-2029 (USD MILLION) 149
TABLE 88 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) 149
TABLE 89 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 90 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 91 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) 151
7.4.1 NEXT-GENERATION SEQUENCING 151
7.4.1.1 Higher speed and better accuracy to fuel segment growth 151
TABLE 92 KEY NEXT-GENERATION SEQUENCING PRODUCTS 152
TABLE 93 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022-2029 (USD MILLION) 153
TABLE 94 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 153
TABLE 95 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 154
TABLE 96 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 154
TABLE 97 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 155
7.4.2 PYROSEQUENCING 155
7.4.2.1 Growing need for genotyping difficult assays with accurate results to augment growth 155
TABLE 98 KEY PYROSEQUENCING PRODUCTS 155
TABLE 99 PYROSEQUENCING MARKET, BY REGION, 2022-2029 (USD MILLION) 156
TABLE 100 NORTH AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 156
TABLE 101 EUROPE: PYROSEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 157
TABLE 102 ASIA PACIFIC: PYROSEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 157
TABLE 103 LATIN AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 157
7.4.3 SANGER SEQUENCING 158
7.4.3.1 Increasing use in small-scale experiments to boost segment growth 158
TABLE 104 KEY SANGER SEQUENCING PRODUCTS 158
TABLE 105 SANGER SEQUENCING MARKET, BY REGION, 2022-2029 (USD MILLION) 159
TABLE 106 NORTH AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 159
TABLE 107 EUROPE: SANGER SEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 160
TABLE 108 ASIA PACIFIC: SANGER SEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 160
TABLE 109 LATIN AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 160
7.5 CAPILLARY ELECTROPHORESIS 161
TABLE 110 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 161
TABLE 111 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY REGION, 2022-2029 (USD MILLION) 162
TABLE 112 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022-2029 (USD MILLION) 162
TABLE 113 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022-2029 (USD MILLION) 163
TABLE 114 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022-2029 (USD MILLION) 163
TABLE 115 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022-2029 (USD MILLION) 164
7.5.1 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM 164
7.5.1.1 Increasing use in determining genetic differences to drive segment 164
TABLE 116 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2022-2029 (USD MILLION) 165
TABLE 117 NORTH AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 165
TABLE 118 EUROPE: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 166
TABLE 119 ASIA PACIFIC: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 166
TABLE 120 LATIN AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 167
7.5.2 RESTRICTION FRAGMENT LENGTH POLYMORPHISM 167
7.5.2.1 Rising demand in forensics and agricultural institutions to support market growth 167
TABLE 121 KEY RESTRICTION FRAGMENT LENGTH POLYMORPHISM PRODUCTS 167
TABLE 122 RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2022-2029 (USD MILLION) 168
TABLE 123 NORTH AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 168
TABLE 124 EUROPE: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 169
TABLE 125 ASIA PACIFIC: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 169
TABLE 126 LATIN AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 170
7.5.3 SINGLE-STRAND CONFORMATION POLYMORPHISM 170
7.5.3.1 Increasing applications in virology to boost segment growth 170
TABLE 127 KEY SINGLE-STRAND CONFORMATION POLYMORPHISM PRODUCTS 170
TABLE 128 SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY REGION, 2022-2029 (USD MILLION) 171
TABLE 129 NORTH AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 171
TABLE 130 EUROPE: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 172
TABLE 131 ASIA PACIFIC: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 172
TABLE 132 LATIN AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 173
7.6 MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY 173
7.6.1 INCREASING APPLICATIONS IN CLINICAL DIAGNOSTICS AND PHARMACOGENOMICS TO AID MARKET GROWTH 173
TABLE 133 KEY MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT PRODUCTS 173
TABLE 134 GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION) 174
TABLE 135 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 174
TABLE 136 EUROPE: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 175
TABLE 137 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 175
TABLE 138 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION) 176
7.7 OTHER TECHNOLOGIES 176
TABLE 139 OTHER GENOTYPING TECHNOLOGIES 176
TABLE 140 GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION) 177
TABLE 141 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 177
TABLE 142 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 178
TABLE 143 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 178
TABLE 144 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 179
8 GENOTYPING ASSAY MARKET, BY APPLICATION 180
8.1 INTRODUCTION 181
TABLE 145 GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 181
8.2 PHARMACOGENOMICS 181
8.2.1 GROWING DEMAND FOR STUDYING ADVERSE DRUG REACTIONS IN CLINICAL TRIALS TO DRIVE MARKET 181
TABLE 146 GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY REGION, 2022-2029 (USD MILLION) 182
TABLE 147 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022-2029 (USD MILLION) 182
TABLE 148 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022-2029 (USD MILLION) 183
TABLE 149 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022-2029 (USD MILLION) 183
TABLE 150 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022-2029 (USD MILLION) 184
8.3 DIAGNOSTICS & PERSONALIZED MEDICINES 184
8.3.1 INCREASING FOCUS ON DEVELOPING DIAGNOSTICS TESTS THROUGH RAPID GENOTYPING TO AID MARKET GROWTH 184
TABLE 151 GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY REGION, 2022-2029 (USD MILLION) 185
TABLE 152 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022-2029 (USD MILLION) 185
TABLE 153 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022-2029 (USD MILLION) 186
TABLE 154 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022-2029 (USD MILLION) 186
TABLE 155 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022-2029 (USD MILLION) 187
8.4 ANIMAL GENETICS 187
8.4.1 NEED TO INCREASE LIVESTOCK POPULATION TO PROPEL MARKET GROWTH 187
TABLE 156 GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY REGION, 2022-2029 (USD MILLION) 188
TABLE 157 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022-2029 (USD MILLION) 188
TABLE 158 EUROPE: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS BY COUNTRY, 2022-2029 (USD MILLION) 189
TABLE 159 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022-2029 (USD MILLION) 189
TABLE 160 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022-2029 (USD MILLION) 190
8.5 AGRICULTURAL BIOTECHNOLOGY 190
8.5.1 INCREASING USE OF PLANT GENOTYPING IN RESEARCH LABORATORIES AND GREENHOUSES TO FUEL MARKET GROWTH 190
TABLE 161 GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2022-2029 (USD MILLION) 191
TABLE 162 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 191
TABLE 163 EUROPE: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 192
TABLE 164 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY BY COUNTRY, 2022-2029 (USD MILLION) 192
TABLE 165 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 193
8.6 OTHER APPLICATIONS 193
TABLE 166 GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 193
TABLE 167 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 194
TABLE 168 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS BY COUNTRY, 2022-2029 (USD MILLION) 194
TABLE 169 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 194
TABLE 170 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 195
9 GENOTYPING ASSAY MARKET, BY END USER 196
9.1 INTRODUCTION 197
TABLE 171 GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 197
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 197
9.2.1 RISING DEMAND FOR PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 197
TABLE 172 GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD MILLION) 198
TABLE 173 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029(USD MILLION) 198
TABLE 174 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029(USD MILLION) 199
TABLE 175 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 199
TABLE 176 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 200
9.3 DIAGNOSTIC LABORATORIES 200
9.3.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINES TO AUGMENT MARKET GROWTH 200
TABLE 177 GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION) 201
TABLE 178 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029(USD MILLION) 201
TABLE 179 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 202
TABLE 180 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 202
TABLE 181 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 203
9.4 ACADEMIC & RESEARCH INSTITUTES 203
9.4.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH 203
TABLE 182 GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION) 204
TABLE 183 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 204
TABLE 184 EUROPE: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 205
TABLE 185 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 205
TABLE 186 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 206
9.5 OTHER END USERS 206
TABLE 187 GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION) 207
TABLE 188 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 207
TABLE 189 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 208
TABLE 190 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 208
TABLE 191 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 209
10 GENOTYPING ASSAY MARKET, BY REGION 210
10.1 INTRODUCTION 211
TABLE 192 GENOTYPING ASSAY MARKET, BY REGION, 2022-2029 (USD MILLION) 211
10.2 NORTH AMERICA 211
FIGURE 40 NORTH AMERICA: GENOTYPING ASSAY MARKET SNAPSHOT 212
TABLE 193 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 212
TABLE 194 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 213
TABLE 195 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 213
TABLE 196 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 213
TABLE 197 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 214
TABLE 198 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 214
TABLE 199 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 215
TABLE 200 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 215
TABLE 201 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 216
TABLE 202 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 216
10.2.1 US 217
10.2.1.1 US to dominate North American genotyping assay market during forecast period 217
TABLE 203 US: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 217
TABLE 204 US: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 218
TABLE 205 US: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 218
TABLE 206 US: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 218
TABLE 207 US: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 219
TABLE 208 US: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 219
TABLE 209 US: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 219
TABLE 210 US: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 220
TABLE 211 US: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 220
10.2.2 CANADA 220
10.2.2.1 Increasing government initiatives and funding for genomics research to drive market 220
TABLE 212 CANADA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 221
TABLE 213 CANADA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 222
TABLE 214 CANADA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 222
TABLE 215 CANADA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 222
TABLE 216 CANADA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 223
TABLE 217 CANADA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 223
TABLE 218 CANADA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 223
TABLE 219 CANADA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 224
TABLE 220 CANADA: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 224
10.2.3 NORTH AMERICA: RECESSION IMPACT 224
10.3 EUROPE 225
TABLE 221 EUROPE: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 225
TABLE 222 EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 226
TABLE 223 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 226
TABLE 224 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 226
TABLE 225 EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 227
TABLE 226 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 227
TABLE 227 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 228
TABLE 228 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 228
TABLE 229 EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 229
TABLE 230 EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 229
10.3.1 GERMANY 229
10.3.1.1 Higher healthcare spending and improved R&D for NGS-based diagnostic tests to augment market growth 229
TABLE 231 GERMANY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 230
TABLE 232 GERMANY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 230
TABLE 233 GERMANY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 231
TABLE 234 GERMANY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 231
TABLE 235 GERMANY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 231
TABLE 236 GERMANY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 232
TABLE 237 GERMANY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 232
TABLE 238 GERMANY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 233
TABLE 239 GERMANY: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 233
10.3.2 UK 233
10.3.2.1 Increasing biotechnology innovation centers and growing government support to fuel market growth 233
TABLE 240 UK: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 234
TABLE 241 UK: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 234
TABLE 242 UK: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 235
TABLE 243 UK: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 235
TABLE 244 UK: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 235
TABLE 245 UK: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 236
TABLE 246 UK: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 236
TABLE 247 UK: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 237
TABLE 248 UK: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 237
10.3.3 FRANCE 237
10.3.3.1 Rising government investments in genomics to boost market growth 237
TABLE 249 FRANCE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 238
TABLE 250 FRANCE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 239
TABLE 251 FRANCE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 239
TABLE 252 FRANCE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 239
TABLE 253 FRANCE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 240
TABLE 254 FRANCE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 240
TABLE 255 FRANCE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 240
TABLE 256 FRANCE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 241
TABLE 257 FRANCE: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 241
10.3.4 ITALY 241
10.3.4.1 Favorable funding scenario in genomics research to support market growth 241
TABLE 258 ITALY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 242
TABLE 259 ITALY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 242
TABLE 260 ITALY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 243
TABLE 261 ITALY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 243
TABLE 262 ITALY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 243
TABLE 263 ITALY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 244
TABLE 264 ITALY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 244
TABLE 265 ITALY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 244
TABLE 266 ITALY: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 245
10.3.5 SPAIN 245
10.3.5.1 Increased R&D funding by government to spur market growth 245
TABLE 267 SPAIN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 245
TABLE 268 SPAIN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 246
TABLE 269 SPAIN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 246
TABLE 270 SPAIN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 246
TABLE 271 SPAIN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 247
TABLE 272 SPAIN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 247
TABLE 273 SPAIN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 247
TABLE 274 SPAIN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 248
TABLE 275 SPAIN: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 248
10.3.6 REST OF EUROPE 248
TABLE 276 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 249
TABLE 277 REST OF EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 249
TABLE 278 REST OF EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 249
TABLE 279 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 250
TABLE 280 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 250
TABLE 281 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 251
TABLE 282 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 251
TABLE 283 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 252
TABLE 284 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 252
10.3.7 EUROPE: RECESSION IMPACT 252
10.4 ASIA PACIFIC 253
FIGURE 41 ASIA PACIFIC: GENOTYPING ASSAY MARKET SNAPSHOT 253
TABLE 285 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 254
TABLE 286 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 254
TABLE 287 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 254
TABLE 288 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 255
TABLE 289 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 255
TABLE 290 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 256
TABLE 291 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 256
TABLE 292 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 256
TABLE 293 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 257
TABLE 294 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 257
10.4.1 CHINA 257
10.4.1.1 Low cost of sequencing procedures and favorable government initiatives to fuel market growth 257
TABLE 295 CHINA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 258
TABLE 296 CHINA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 258
TABLE 297 CHINA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 259
TABLE 298 CHINA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 259
TABLE 299 CHINA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 259
TABLE 300 CHINA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 260
TABLE 301 CHINA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 260
TABLE 302 CHINA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 261
TABLE 303 CHINA: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 261
10.4.2 JAPAN 261
10.4.2.1 Launch of technologically advanced sequencing platforms to drive market 261
TABLE 304 JAPAN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 262
TABLE 305 JAPAN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 262
TABLE 306 JAPAN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 263
TABLE 307 JAPAN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 263
TABLE 308 JAPAN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 263
TABLE 309 JAPAN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 264
TABLE 310 JAPAN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 264
TABLE 311 JAPAN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 265
TABLE 312 JAPAN: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 265
10.4.3 INDIA 265
10.4.3.1 Increasing research on gene expression therapies and decreasing cost of sequencing to augment market growth 265
TABLE 313 INDIA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 267
TABLE 314 INDIA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 267
TABLE 315 INDIA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 267
TABLE 316 INDIA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 268
TABLE 317 INDIA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 268
TABLE 318 INDIA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 269
TABLE 319 INDIA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 269
TABLE 320 INDIA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 270
TABLE 321 INDIA: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 270
10.4.4 REST OF ASIA PACIFIC 270
TABLE 322 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 271
TABLE 323 REST OF ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 271
TABLE 324 REST OF ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 271
TABLE 325 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 272
TABLE 326 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 272
TABLE 327 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 273
TABLE 328 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 273
TABLE 329 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 274
TABLE 330 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 274
10.4.5 ASIA PACIFIC: RECESSION IMPACT 274
10.5 LATIN AMERICA 275
TABLE 331 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 275
TABLE 332 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 275
TABLE 333 LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 276
TABLE 334 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 276
TABLE 335 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 276
TABLE 336 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 277
TABLE 337 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 277
TABLE 338 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 277
TABLE 339 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 278
TABLE 340 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 278
10.5.1 BRAZIL 278
10.5.1.1 Establishment of manufacturing facilities by key players to propel market growth 278
TABLE 341 BRAZIL: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 279
TABLE 342 BRAZIL: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 279
TABLE 343 BRAZIL: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 280
TABLE 344 BRAZIL: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 280
TABLE 345 BRAZIL: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 280
TABLE 346 BRAZIL: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 281
TABLE 347 BRAZIL: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 281
TABLE 348 BRAZIL: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 282
TABLE 349 BRAZIL: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 282
10.5.2 MEXICO 282
10.5.2.1 Favorable trade agreements and increased government support to boost market growth 282
TABLE 350 MEXICO: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 283
TABLE 351 MEXICO: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 283
TABLE 352 MEXICO: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 284
TABLE 353 MEXICO: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 284
TABLE 354 MEXICO: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 284
TABLE 355 MEXICO: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 285
TABLE 356 MEXICO: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 285
TABLE 357 MEXICO: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 286
TABLE 358 MEXICO: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 286
10.5.3 REST OF LATIN AMERICA 286
TABLE 359 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 287
TABLE 360 REST OF LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 287
TABLE 361 REST OF LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 287
TABLE 362 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 288
TABLE 363 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 288
TABLE 364 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 289
TABLE 365 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 289
TABLE 366 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 290
TABLE 367 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 290
10.5.4 LATIN AMERICA: RECESSION IMPACT 290
10.6 MIDDLE EAST & AFRICA 291
10.6.1 INCREASING ADOPTION OF GENETIC TESTING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET 291
TABLE 368 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 291
TABLE 369 MIDDLE EAST & AFRICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 292
TABLE 370 MIDDLE EAST & AFRICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 292
TABLE 371 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 292
TABLE 372 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 293
TABLE 373 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 293
TABLE 374 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 293
TABLE 375 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 294
TABLE 376 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 294
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 294
10.7 GCC COUNTRIES 295
10.7.1 IMPROVED HEALTHCARE INFRASTRUCTURE AND RISE IN LIFESTYLE-RELATED DISEASES TO FUEL MARKET GROWTH 295
TABLE 377 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) 295
TABLE 378 GCC COUNTRIES: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION) 296
TABLE 379 GCC COUNTRIES: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 296
TABLE 380 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 296
TABLE 381 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION) 297
TABLE 382 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION) 297
TABLE 383 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION) 297
TABLE 384 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 298
TABLE 385 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION) 298
10.7.2 GCC COUNTRIES: RECESSION IMPACT 298
11 COMPETITIVE LANDSCAPE 300
11.1 INTRODUCTION 300
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 300
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET 300
TABLE 386 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET 300
11.3 REVENUE ANALYSIS 301
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN GENOTYPING ASSAY MARKET (2021-2023) 302
11.4 MARKET SHARE ANALYSIS 302
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GENOTYPING ASSAY MARKET (2023) 302
TABLE 387 GENOTYPING ASSAY MARKET: DEGREE OF COMPETITION 303
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 304
11.5.1 STARS 304
11.5.2 EMERGING LEADERS 304
11.5.3 PERVASIVE PLAYERS 304
11.5.4 PARTICIPANTS 304
FIGURE 44 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 305
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 305
11.5.5.1 Company footprint 305
FIGURE 45 GENOTYPING ASSAY MARKET: COMPANY FOOTPRINT 305
11.5.5.2 Product & service footprint 306
TABLE 388 GENOTYPING ASSAY MARKET: PRODUCT & SERVICE FOOTPRINT 306
11.5.5.3 Technology footprint 306
TABLE 389 GENOTYPING ASSAY MARKET: TECHNOLOGY FOOTPRINT 306
11.5.5.4 Application footprint 306
TABLE 390 GENOTYPING ASSAY MARKET: APPLICATION FOOTPRINT 306
11.5.5.5 Region footprint 307
TABLE 391 GENOTYPING ASSAY MARKET: REGION FOOTPRINT 307
11.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2023 307
11.6.1 PROGRESSIVE COMPANIES 307
11.6.2 RESPONSIVE COMPANIES 307
11.6.3 DYNAMIC COMPANIES 307
11.6.4 STARTING BLOCKS 307
FIGURE 46 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 308
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 308
TABLE 392 GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 308
TABLE 393 GENOTYPING ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 309
11.7 VALUATION & FINANCIAL METRICS 309
FIGURE 47 EV/EBITDA OF KEY VENDORS 309
FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 310
11.8 BRAND/PRODUCT COMPARISON 310
FIGURE 49 GENOTYPING ASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 310
11.8.1 THERMO FISHER SCIENTIFIC INC. 311
11.8.2 AGILENT TECHNOLOGIES, INC. 311
11.8.3 QIAGEN 311
11.8.4 ILLUMINA, INC. 311
11.9 COMPETITIVE SCENARIO 311
11.9.1 PRODUCT LAUNCHES, DEVELOPMENTS, AND APPROVALS 312
TABLE 394 GENOTYPING ASSAY MARKET: PRODUCT LAUNCHES, DEVELOPMENTS, AND APPROVALS, JANUARY 2020-MARCH 2024 312
11.9.2 DEALS 313
TABLE 395 GENOTYPING ASSAY MARKET: DEALS, JANUARY 2020-MARCH 2024 313
12 COMPANY PROFILES 314
12.1 KEY PLAYERS 314
(Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses and Competitive threats)*
12.1.1 THERMO FISHER SCIENTIFIC INC. 314
TABLE 396 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 314
FIGURE 50 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 315
TABLE 397 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 315
TABLE 398 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020-MARCH 2024 319
TABLE 399 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2020-MARCH 2024 321
12.1.2 ILLUMINA, INC. 322
TABLE 400 ILLUMINA, INC.: COMPANY OVERVIEW 322
FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) 323
TABLE 401 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 323
TABLE 402 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2020-MARCH 2024 327
TABLE 403 ILLUMINA, INC.: DEALS, JANUARY 2020-MARCH 2024 328
TABLE 404 ILLUMINA, INC.: EXPANSIONS, JANUARY 2020-MARCH 2024 331
12.1.3 DANAHER CORPORATION 332
TABLE 405 DANAHER CORPORATION: COMPANY OVERVIEW 332
FIGURE 52 DANAHER CORPORATION: COMPANY SNAPSHOT (2023) 333
TABLE 406 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 333
TABLE 407 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2020-MARCH 2024 335
TABLE 408 DANAHER CORPORATION: DEALS, JANUARY 2020-MARCH 2024 335
12.1.4 QIAGEN 337
TABLE 409 QIAGEN: COMPANY OVERVIEW 337
FIGURE 53 QIAGEN: COMPANY SNAPSHOT (2023) 338
TABLE 410 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 338
TABLE 411 QIAGEN: PRODUCT LAUNCHES AND DEVELOPMENTS, JANUARY 2020-MARCH 2024 340
TABLE 412 QIAGEN: DEALS, JANUARY 2020-MARCH 2024 340
12.1.5 EUROFINS SCIENTIFIC 342
TABLE 413 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 342
FIGURE 54 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023) 343
TABLE 414 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 343
TABLE 415 EUROFINS SCIENTIFIC: PRODUCT AND SERVICE LAUNCHES, JANUARY 2020-MARCH 2024 344
TABLE 416 EUROFINS SCIENTIFIC: DEALS, JANUARY 2020-MARCH 2024 345
12.1.6 F. HOFFMANN-LA ROCHE LTD. 346
TABLE 417 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 346
FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 347
TABLE 418 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 347
TABLE 419 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2020-MARCH 2024 348
TABLE 420 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2020-MARCH 2024 349
12.1.7 AGILENT TECHNOLOGIES, INC. 350
TABLE 421 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 350
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 351
TABLE 422 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 351
TABLE 423 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020-MARCH 2024 356
12.1.8 BIO-RAD LABORATORIES, INC. 357
TABLE 424 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 357
FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 358
TABLE 425 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 358
12.1.9 MERCK KGAA 361
TABLE 426 MERCK KGAA: COMPANY OVERVIEW 361
FIGURE 58 MERCK KGAA: COMPANY SNAPSHOT (2023) 362
TABLE 427 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 362
12.1.10 STANDARD BIOTOOLS 364
TABLE 428 STANDARD BIOTOOLS: COMPANY OVERVIEW 364
FIGURE 59 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2023) 365
TABLE 429 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 365
12.2 OTHER PLAYERS 367
12.2.1 REVVITY 367
TABLE 430 REVVITY: COMPANY OVERVIEW 367
12.2.2 PACBIO 368
TABLE 431 PACBIO: COMPANY OVERVIEW 368
12.2.3 LUMINEX CORPORATION (A DIASORIN COMPANY) 370
TABLE 432 LUMINEX CORPORATION (A DIASORIN COMPANY): COMPANY OVERVIEW 370
12.2.4 OXFORD NANOPORE TECHNOLOGIES PLC 371
TABLE 433 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW 371
12.2.5 GENEWIZ, INC. 372
TABLE 434 GENEWIZ, INC.: COMPANY OVERVIEW 372
12.2.6 TAKARA BIO INC. 374
TABLE 435 TAKARA BIO INC.: COMPANY OVERVIEW 374
12.2.7 BGI GROUP 375
TABLE 436 BGI GROUP: COMPANY OVERVIEW 375
12.2.8 PROMEGA CORPORATION 376
TABLE 437 PROMEGA CORPORATION: COMPANY OVERVIEW 376
12.2.9 NOVOGENE CO., LTD. 377
TABLE 438 NOVOGENE CO., LTD.: COMPANY OVERVIEW 377
12.2.10 GENSCRIPT 378
TABLE 439 GENSCRIPT: COMPANY OVERVIEW 378
12.2.11 NEW ENGLAND BIOLABS 379
TABLE 440 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 379
12.2.12 PARAGON GENOMICS, INC. 379
TABLE 441 PARAGON GENOMICS, INC.: COMPANY OVERVIEW 379
12.2.13 NEOGENOMICS LABORATORIES 380
TABLE 442 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW 380
12.2.14 TECAN TRADING AG 380
TABLE 443 TECAN TRADING AG: COMPANY OVERVIEW 380
12.2.15 GENOTYPIC TECHNOLOGY PVT. LTD. 381
TABLE 444 GENOTYPIC TECHNOLOGY PVT. LTD.: COMPANY OVERVIEW 381
*Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
13 APPENDIX 382
13.1 DISCUSSION GUIDE 382
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 385
13.3 CUSTOMIZATION OPTIONS 387
13.4 RELATED REPORTS 387
13.5 AUTHOR DETAILS 388
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security